Request Demo
Last update 24 May 2025
IBC-0966
Last update 24 May 2025
Overview
Basic Info
Drug Type Fusion protein |
Synonyms IBC 0966, IBC-0966 |
Target |
Action inhibitors |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), SIRPα inhibitors(Signal-regulatory protein alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with IBC-0966NCT04980690
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors
100 Clinical Results associated with IBC-0966
Login to view more data
100 Translational Medicine associated with IBC-0966
Login to view more data
100 Patents (Medical) associated with IBC-0966
Login to view more data
100 Deals associated with IBC-0966
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 2 | China | 31 Aug 2021 | |
| Anaplastic Large-Cell Lymphoma | Phase 2 | China | 31 Aug 2021 | |
| Enteropathy-Associated T-Cell Lymphoma | Phase 2 | China | 31 Aug 2021 | |
| Extranodal NK-T-Cell Lymphoma | Phase 2 | China | 31 Aug 2021 | |
| hepatosplenic T-cell lymphoma | Phase 2 | China | 31 Aug 2021 | |
| Immunoblastic Lymphadenopathy | Phase 2 | China | 31 Aug 2021 | |
| metastatic non-small cell lung cancer | Phase 2 | China | 31 Aug 2021 | |
| Nasopharyngeal Carcinoma | Phase 2 | China | 31 Aug 2021 | |
| Peripheral T-Cell Lymphoma | Phase 2 | China | 31 Aug 2021 | |
| Squamous cell carcinoma of head and neck metastatic | Phase 2 | China | 31 Aug 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free